For a variety of reasons, one could say that ZIOPHARM Oncology (ZIOP), a tiny little-known biopharmaceutical company developing several anti-cancer drugs, is now several notches above its peers in the highly volatile and competitive biotech industry.
It has, first of all, attracted several of the largest big-name investment groups, a nearly impossible task to achieve for most small biotechs. Fidelity Management, which leads a list of reputable institutional investors that has accumulated shares in ZIOPHARM, is now the largest shareholder with a 13.75% stake.
The second largest shareholder with more than 12% is Intrexon Corp., whose Chairman and CEO Randal J. Kirk, a widely known leader in the life sciences industry whose reputation as a founder of several successful biotech companies and savvy deal maker is almost unmatched. Other big shareholders include Merlin Biomed Group, which has purchased a 3.64% stake; BlackRock Fund Advisors (BLK) and BlackRock Institutional Trust which, combined, own more than 3% of the stock; Essex Woodlands Health Ventures, which has a 2.9% stake interest; Vanguard Group, with 1.29%; and the Middle East money group, Abu Dhabi Investment, which owns 1.50%.
Curated content use the image to finish the article from the original source.
- Ziopharm vows to wow cancer field with synthetic biology drugs (fiercebiotech.com)
- Synthetic Biology companies Ziopharm and Intrexon (nextbigfuture.com)
- ZIOPHARM Oncology Files Investigational New Drug Application For Ad-RTS-IL-12, A Novel DNA-Based Oncology Therapeutic Candidate (medicalnewstoday.com)
- ACT Biotech, Scooping Up Bayer’s Cast-Off, Shows Promise With Stomach Cancer Drug (xconomy.com)
- Biotech billionaire raises $100M for synthetic biology venture Intrexon (fiercebiotech.com)
Latest posts by Tom George (see all)
- New Digital Trends In Today’s Smartphone-Obsessed World - September 6, 2016
- 5 Things a Recruiter Looks for in a Resume - August 30, 2016
- Obtaining Legal Immunity for Pet Cohabitation - August 30, 2016